AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 196.51B +18.7% |
| Revenue (ttm) | 45.77B +9.9% |
| Net Income | 7.87B +33.7% |
| EPS | 5.03 +33.6% |
| Shares Out | 1.55B |
| PE Ratio | 25.20 |
| Forward PE | 16.00 |
| Dividend | 2.36 (1.86%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 348,239 |
| Open | 12,736 |
| Previous Close | 12,670 |
| Day's Range | 12,694 - 12,920 |
| 52-Week Range | 10,524 - 15,732 |
| Beta | 0.22 |
| Analysts | Buy |
| Price Target | 15,927.90 (+24.03%) |
| Earnings Date | Jul 27, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is 15,928p, which is an increase of 24.03% from the latest price.
News
AstraZeneca Quarterly report: Q2 2026
AstraZeneca has published its Q2 2026 quarterly earnings report on July 27, 2026.
AstraZeneca Slides: Q2 2026
AstraZeneca has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 27, 2026.
AstraZeneca's rare disease drug misses main goal in late-stage trial
AstraZeneca said on Monday its rare disease drug Ultomiris failed a late-stage trial in patients with a blood vessel complication following a stem cell transplant, the latest in a series of setbacks...
AstraZeneca Posts Sales Growth on Oncology Strength
The U.K. drugmaker's revenue rose 5% when adjusted for currency changes, driven by growth in oncology sales.
AstraZeneca CFO: Very confident we will hit $80 billion revenue target
AstraZeneca CFO, Aradhana Sarin, discusses half-year earnings, the company's drug development pipeline, and its oral GLP-1.
Oil price slides as US and Iran pause fire; cancer treatments help AstraZeneca beat profit forecasts – business live
Rolling coverage of the latest economic and financial news Good morning, and welcome to our rolling coverage of business, the financial markets and the world economy. Oil prices have fallen more than ...
AstraZeneca Q2 Pre-tax Profit Drops, Revenues Rise; Confirms FY26 Outlook
(RTTNews) - British drug major AstraZeneca PLC (AZN, AZN.L) reported Monday lower pre-tax pofit in its second quarter, despite higher revenues.
AstraZeneca beats second-quarter profit expectations, holds outlook
AstraZeneca topped second-quarter profit expectations and backed its 2026 forecasts on Monday on demand for its cancer and heart disease therapies, as the drugmaker sought to quell concerns o...
Upcoming Earnings Report: AstraZeneca PLC (AZN) and More Set to Release
Upcoming Earnings Report: AstraZeneca PLC (AZN) and More Set to Release
AstraZeneca Q2 Earnings Preview: Can Tagrisso, Imfinzi And Farxiga Sustain Momentum?
(RTTNews) - AstraZeneca PLC (AZN) is scheduled to report the second-quarter results on July 27, 2026.
AstraZeneca (AZN) Earnings Report Anticipated as Wall Street Closes Mixed
AstraZeneca (AZN) Earnings Report Anticipated as Wall Street Closes Mixed
Pre-Market Earnings Report for July 27, 2026 : AZN, BOH, ARLP, KOF, HOPE, LKFN, HBT, NBN, BMRC, PERF
The following companies are expected to report earnings prior to market open on 07/27/2026. Visit our Earnings Calendar for a full list of expected earnings releases.AstraZeneca PLC (AZN)is reporting ...
Weekly Buzz: AZN, GSK JNJ Approvals; CUV Layoff, REGN, HALO, Samsun Deals, LLY, CLDX Data
(RTTNews) - This week, the biotech sector was marked by FDA and EU approvals, strategic acquisitions, and a major workforce restructuring. Clinical trial updates delivered both breakthroughs and setba...
AstraZeneca PLC (LSE:AZN) Q2 2026: Everything You Need To Know Ahead Of Earnings
AstraZeneca PLC (LSE:AZN) Q2 2026: Everything You Need To Know Ahead Of Earnings
AstraZeneca (AZN) Secures EU Approval Recommendation for Breast Cancer Treatment
AstraZeneca (AZN) Secures EU Approval Recommendation for Breast Cancer Treatment
AstraZeneca Reports Q2 Earnings Next Week. What Investors Should Expect.
Drugs giant AstraZeneca ($AZN) is set to report its Q2 earnings next week – July 27. Let’s look at what investors should expect. The company’s share price is down 11%…
AstraZeneca (AZN) Seeks EU Approval for Trixeo Aerosphere in Asthma Treatment
AstraZeneca (AZN) Seeks EU Approval for Trixeo Aerosphere in Asthma Treatment
AstraZeneca, Daiichi’s Enhertu with pertuzumab recommended for approval in EU
AstraZeneca (AZN) and Daiichi Sankyo’s Enhertu in combination with pertuzumab has been recommended for approval in the European Union, EU, for the 1st-line treatment of adult patients with unresectabl...
AstraZeneca announces Trixeo Aerosphere recommended for approval in EU
AstraZeneca’s (AZN) fixed-dose triple-combination Trixeo Aerosphere has been recommended for approval in the European Union, EU, for the maintenance treatment of asthma in patients 12 years of age and...
FTSE 100 shares to watch: Lloyds, Barclays, IAG, NatWest, GSK, AstraZeneca
The FTSE 100 Index was little changed this week as investors assessed the escalating UK-Iran crisis, the ongoing US earnings season, and a series of key UK economic releases. Market participants diges...
AstraZeneca 'magic' faces rare test after trial failure, share slide
AstraZeneca's long-time CEO Pascal Soriot has rarely put a foot wrong. The company's shares have more that quadrupled in price during his 14-year tenure, soaring above the wider FTSE 100 index and mai...
Edwards Lifesciences Q2 Earnings Call Highlights
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHEdwards Lifesciences (NYSE:EW) reported stronger-than-expected second-quarter 2026 results, with management pointing to broad growth acro...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN). Such investors are advised to con...
AstraZeneca's (AZN) Etcamah Secures EU Approval for Breast Cancer Treatment
AstraZeneca's (AZN) Etcamah Secures EU Approval for Breast Cancer Treatment
AstraZeneca announces Etcamah with CDK4/6 inhibitor approved in EU
AstraZeneca’s (AZN) Etcamah in combination with a cyclin-dependent kinase, CDK, 4/6 inhibitor has been approved in the European Union, EU, for the treatment of adult patients with estrogen receptor-po...